Hepatic Predictors of Mortality in Severe Acute Respiratory Syndrome Coronavirus 2: Role of Initial Aspartate Aminotransferase/Alanine Aminotransferase and Preexisting Cirrhosis

Shalom Z. Frager, James Szymanski, Jonathan M. Schwartz, Hatef S. Massoumi, Milan Kinkhabwala, Allan W. Wolkoff – 11 November 2020 – The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) is the causative agent of coronavirus disease 2019 (COVID‐19). The presenting symptoms of this virus are variable, and there is an increasing body of literature on risk factors for mortality.

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Rohit Loomba, Mazen Noureddin, Kris V. Kowdley, Anita Kohli, Aasim Sheikh, Guy Neff, Bal Raj Bhandari, Nadege Gunn, Stephen H. Caldwell, Zachary Goodman, Ilan Wapinski, Murray Resnick, Andrew H. Beck, Dora Ding, Catherine Jia, Jen‐Chieh Chuang, Ryan S. Huss, Chuhan Chung, G. Mani Subramanian, Robert P. Myers, Keyur Patel, Brian B. Borg, Reem Ghalib, Heidi Kabler, John Poulos, Ziad Younes, Magdy Elkhashab, Tarek Hassanein, Rajalakshmi Iyer, Peter Ruane, Mitchell L. Shiffman, Simone Strasser, Vincent Wai‐Sun Wong, Naim Alkhouri, ATLAS Investigators – 10 November 2020

Innovations in Hepatitis C Screening and Treatment

Arpan A. Patel, Aileen Bui, Eian Prohl, Debika Bhattacharya, Su Wang, Andrea D. Branch, Ponni V. Perumalswami – 10 November 2020 – New therapies offer hope for a cure to millions of persons living with hepatitis C virus (HCV) infection. HCV elimination is a global goal that will be difficult to achieve using the traditional paradigms of diagnosis and care. The current standard has evolved toward universal HCV screening and treatment, to achieve elimination goals. There are several steps between HCV diagnosis and cure with major barriers along the way.

Coronavirus Disease 2019 in the Early Postoperative Period of Liver Transplantation: Is the Outcome Really So Positive?

Daniel Reis Waisberg, Edson Abdala, Lucas Souto Nacif, Liliana Ducatti, Luciana Bertocco Haddad, Rodrigo Bronze Martino, Rafael Soares Pinheiro, Rubens Macedo Arantes, Flavio Henrique Galvao, Larissa Nunes Gouveia, Debora Raquel Terrabuio, George Felipe Darce, Vinicius Rocha‐Santos, Wellington Andraus, Luiz Augusto Carneiro‐D’Albuquerque – 9 November 2020

Multicenter, Double‐Blind, Randomized Trial of Emricasan in Hepatitis C–Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis

Ethan M. Weinberg, Michael P. Curry, Catherine T. Frenette, Fredric G. Regenstein, Eugene R. Schiff, Zachary D. Goodman, James M. Robinson, Jean L. Chan, Joanne C. Imperial, K. Rajender Reddy – 8 November 2020 – Despite achieving sustained virologic response (SVR) to hepatitis C virus (HCV) therapy, there remains a post liver transplantation population with advanced fibrosis/cirrhosis. Emricasan is an orally active, pan‐caspase inhibitor that suppresses apoptosis and inflammation, potentially decreasing hepatic inflammation and fibrosis.

Impacts of Early Kasai Portoenterostomy on Short‐Term and Long‐Term Outcomes of Biliary Atresia

Ryuji Okubo, Masaki Nio, Hideyuki Sasaki, the Japanese Biliary Atresia Society – 8 November 2020 – There are discrepancies regarding the clinical impact of age at Kasai portoenterostomy (KP) on surgical outcomes. Hence, we re‐assessed the clinical significance of age at KP. We analyzed 224 patients with type III (atresia of bile duct at the porta hepatis) biliary atresia at Tohoku University Hospital. We classified patients into two groups: KP at ≤60 days of age (group TE) and >60 days of age (group TL).

Subscribe to